Open AccessEfficacy and safety of onabotulinumtoxinA with standardized physiotherapy for the treatment of pediatric lower limb spasticity: A randomized, placebo-controlled, phase III clinical trial
Author(s) -
Rozalina Dimitrova,
Heakyung Kim,
Jill Meilahn,
Henry G. Chambers,
Brad A. Racette,
Marcin Bonikowski,
Eun Sook Park,
Emily McCusker,
Chengcheng Liu,
Mitchell F. Brin
Publication year - 2022
Publication title -
neurorehabilitation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.611
H-Index - 65
eISSN - 1878-6448
pISSN - 1053-8135
DOI - 10.3233/nre-210070
Subject(s) - medicine , randomized controlled trial , spasticity , placebo , physical therapy , physical medicine and rehabilitation , surgery , alternative medicine , pathology
BACKGROUND: Spasticity is common in cerebral palsy and can result in pain and diminished health-related quality of life. OBJECTIVE: To evaluate the safety and efficacy of onabotulinumtoxinA for lower limb spasticity treatment in children with cerebral palsy. METHODS: In this registrational phase 3, multinational, randomized, double-blind, placebo-controlled trial (NCT01603628), children (2–< 17 years) with cerebral palsy and ankle spasticity (Modified Ashworth Scale-Bohannon [MAS] score≥2) were randomized 1 : 1 : 1 to standardized physical therapy and onabotulinumtoxinA (4 or 8 U/kg), or placebo. Primary endpoint was average change from baseline at weeks 4 and 6 in MAS ankle score. Secondary endpoints included the Modified Tardieu Scale (MTS) and Global Attainment Scale (GAS). RESULTS: 381 participants were randomized. MAS scores averaged at weeks 4 and 6 were significantly reduced with both onabotulinumtoxinA doses (8 U/kg: –1.06, p = 0.010; 4 U/kg: –1.01, p = 0.033) versus placebo (–0.8). Significant improvements in average dynamic component of spasticity, measured by MTS, and in function, measured by GAS, were observed at several time points with both onabotulinumtoxinA doses versus placebo. Most adverse events were mild or moderate. CONCLUSIONS: OnabotulinumtoxinA was well tolerated and effective in reducing lower limb spasticity and improving functional outcomes versus placebo in children.